Hangzhou Minsheng Healthcare Co., Ltd. (SHE:301507)
14.86
0.00 (0.00%)
At close: May 6, 2026
SHE:301507 Revenue
Hangzhou Minsheng Healthcare had revenue of 317.49M CNY in the quarter ending March 31, 2026, with 16.95% growth. This brings the company's revenue in the last twelve months to 827.65M, up 22.06% year-over-year. In the year 2025, Hangzhou Minsheng Healthcare had annual revenue of 781.63M with 21.89% growth.
Revenue (ttm)
827.65M
Revenue Growth
+22.06%
P/S Ratio
6.40
Revenue / Employee
1.61M
Employees
514
Market Cap
5.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 781.63M | 140.38M | 21.89% |
| Dec 31, 2024 | 641.25M | 59.52M | 10.23% |
| Dec 31, 2023 | 581.73M | 34.61M | 6.33% |
| Jan 1, 2023 | 547.12M | 57.54M | 11.75% |
| Dec 31, 2021 | 489.58M | 50.15M | 11.41% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nanjing Pharmaceutical Group Company | 54.56B |
| Zhejiang Int'l Group | 33.84B |
| Zhejiang Zhenyuan Share | 1.96B |
| Shanghai Shenqi Pharmaceutical Investment Management | 1.90B |
| GuangYuYuan Chinese Herbal Medicine | 1.44B |
| Shanghai InnoStar Bio-tech | 812.23M |
| Chongqing Lummy Pharmaceutical | 759.50M |
| Hangzhou Bio-Sincerity Pharma-Tech | 590.33M |